{"slug":"registry-only","tag":"registry-only","variants":["registry-only"],"description":"Products and companies known so far only from a trial registry entry, with little else published.","count":101,"kinds":{"company":15,"drug":86},"related":[{"slug":"pipeline","tag":"pipeline","shared":86},{"slug":"china","tag":"china","shared":15}],"records":[{"id":"chengdu-zenitar-biomedical-technology","kind":"company","name":"Chengdu Zenitar Biomedical Technology","route":"/companies/chengdu-zenitar-biomedical-technology/","tldr":"Chengdu Zenitar Biomedical Technology is a Chinese developer in Chengdu that sponsors 6 registered cancer trials of Purinostat and Purinostat Mesylate."},{"id":"jacobio-pharmaceuticals","kind":"company","name":"Jacobio Pharmaceuticals","route":"/companies/jacobio-pharmaceuticals/","tldr":"Jacobio Pharmaceuticals is a Chinese developer in Beijing that sponsors 6 registered cancer trials of JAB-30355 and JAB-2485."},{"id":"beijing-konruns-pharmaceutical","kind":"company","name":"Beijing Konruns Pharmaceutical","route":"/companies/beijing-konruns-pharmaceutical/","tldr":"Beijing Konruns Pharmaceutical is a Chinese developer in Beijing that sponsors 5 registered cancer trials of KC1036 and S-1."},{"id":"beijing-mabworks-biotech","kind":"company","name":"Beijing Mabworks Biotech","route":"/companies/beijing-mabworks-biotech/","tldr":"Beijing Mabworks Biotech is a Chinese developer in Beijing that sponsors 4 registered cancer trials of MBS314 and MBS303."},{"id":"binhui-biopharmaceutical","kind":"company","name":"Binhui Biopharmaceutical","route":"/companies/binhui-biopharmaceutical/","tldr":"Binhui Biopharmaceutical is a Chinese developer in Wuhan that sponsors 4 registered cancer trials of OH2 and HX008."},{"id":"beijing-pearl-biotechnology-limited-liability-company","kind":"company","name":"Beijing Pearl Biotechnology Limited Liability Company","route":"/companies/beijing-pearl-biotechnology-limited-liability-company/","tldr":"Beijing Pearl Biotechnology Limited Liability Company is a Chinese developer in Beijing that sponsors 3 registered cancer trials of PLB1001 and Temozolomide."},{"id":"beijing-scitech-mq-pharmaceuticals","kind":"company","name":"Beijing Scitech-Mq Pharmaceuticals","route":"/companies/beijing-scitech-mq-pharmaceuticals/","tldr":"Beijing Scitech-Mq Pharmaceuticals is a Chinese developer in Beijing that sponsors 3 registered cancer trials of ST-1898."},{"id":"immvira-pharma","kind":"company","name":"ImmVira Pharma","route":"/companies/immvira-pharma/","tldr":"ImmVira Pharma is a Chinese developer in Shenzhen that sponsors 3 registered cancer trials of Herpes Virus C5252 and T3011."},{"id":"shandong-new-time-pharmaceutical","kind":"company","name":"Shandong New Time Pharmaceutical","route":"/companies/shandong-new-time-pharmaceutical/","tldr":"Shandong New Time Pharmaceutical is a Chinese developer in Shandong that sponsors 3 registered cancer trials of F182112 and F182112 single-agent."},{"id":"beijing-gene-key-life-technology","kind":"company","name":"Beijing Gene Key Life Technology","route":"/companies/beijing-gene-key-life-technology/","tldr":"Beijing Gene Key Life Technology is a Chinese developer in Beijing that sponsors 2 registered cancer trials of GKL-006."},{"id":"beijing-tide-pharmaceutical","kind":"company","name":"Beijing Tide Pharmaceutical","route":"/companies/beijing-tide-pharmaceutical/","tldr":"Beijing Tide Pharmaceutical is a Chinese developer in Beijing that sponsors 2 registered cancer trials of TCC1727."},{"id":"henan-genuine-biotech","kind":"company","name":"Henan Genuine Biotech","route":"/companies/henan-genuine-biotech/","tldr":"Henan Genuine Biotech is a Chinese developer in Henan that sponsors 2 registered cancer trials of GEN-725 and Dositinib."},{"id":"nanjing-immunophage-biotech","kind":"company","name":"Nanjing Immunophage Biotech","route":"/companies/nanjing-immunophage-biotech/","tldr":"Nanjing Immunophage Biotech is a Chinese developer in Nanjing that sponsors 2 registered cancer trials of IPG1094 and IPG7236."},{"id":"tj-biopharma","kind":"company","name":"TJ Biopharma","route":"/companies/tj-biopharma/","tldr":"TJ Biopharma is a Chinese developer in Shanghai that sponsors 2 registered cancer trials of Uliledlimab and Sintilimab."},{"id":"zhuhai-yufan-biotechnologies","kind":"company","name":"Zhuhai Yufan Biotechnologies","route":"/companies/zhuhai-yufan-biotechnologies/","tldr":"Zhuhai Yufan Biotechnologies is a Chinese developer in Zhuhai that sponsors 2 registered cancer trials of PRJ1-3024."},{"id":"azd0120","kind":"drug","name":"AZD0120","route":"/drugs/azd0120/","status":"phase-3","tldr":"AZD0120 is a car-t cell therapy from AstraZeneca, in registered phase 3 trials for multiple myeloma."},{"id":"utomilumab","kind":"drug","name":"Utomilumab","route":"/drugs/utomilumab/","status":"phase-3","tldr":"Utomilumab is a monoclonal antibody from Pfizer, in registered phase 3 trials for ovarian cancer."},{"id":"alisertib","kind":"drug","name":"Alisertib","route":"/drugs/alisertib/","status":"phase-2","tldr":"Alisertib is an oral serine/threonine kinase inhibitor from Puma Biotechnology, Inc., in registered phase 2 trials for small-cell lung cancer."},{"id":"roginolisib","kind":"drug","name":"Roginolisib","route":"/drugs/roginolisib/","status":"phase-2","tldr":"Roginolisib is an oral pi3k inhibitor from iOnctura, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer."},{"id":"regn7075","kind":"drug","name":"REGN7075","route":"/drugs/regn7075/","status":"phase-2","tldr":"REGN7075 is a bispecific antibody from Regeneron Pharmaceuticals, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer."},{"id":"zalifrelimab","kind":"drug","name":"Zalifrelimab","route":"/drugs/zalifrelimab/","status":"phase-2","tldr":"Zalifrelimab is a monoclonal antibody from Nelum Corp, in registered phase 2 trials for pancreatic ductal adenocarcinoma."},{"id":"balstilimab","kind":"drug","name":"Balstilimab","route":"/drugs/balstilimab/","status":"phase-2","tldr":"Balstilimab is a monoclonal antibody from Agenus Inc., in registered phase 2 trials for colorectal cancer."},{"id":"tst001","kind":"drug","name":"TST001","route":"/drugs/tst001/","status":"phase-2","tldr":"TST001 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer."},{"id":"tno155","kind":"drug","name":"TNO155","route":"/drugs/tno155/","status":"phase-2","tldr":"TNO155 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer."},{"id":"parsaclisib","kind":"drug","name":"Parsaclisib","route":"/drugs/parsaclisib/","status":"phase-2","tldr":"Parsaclisib is an oral pi3k inhibitor from Incyte Corporation, in registered phase 2 trials for diffuse large B-cell lymphoma."},{"id":"feladilimab","kind":"drug","name":"Feladilimab","route":"/drugs/feladilimab/","status":"phase-2","tldr":"Feladilimab is a monoclonal antibody from GlaxoSmithKline, in registered phase 2 trials for multiple myeloma."},{"id":"amt-116","kind":"drug","name":"AMT-116","route":"/drugs/amt-116/","status":"phase-2","tldr":"AMT-116 is an antibody-drug conjugate from Multitude Therapeutics Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer."},{"id":"azd8421","kind":"drug","name":"AZD8421","route":"/drugs/azd8421/","status":"phase-2","tldr":"AZD8421 is a small-molecule inhibitor from AstraZeneca, in registered phase 2 trials for ovarian cancer."},{"id":"enb003","kind":"drug","name":"ENB003","route":"/drugs/enb003/","status":"phase-2","tldr":"ENB003 is a small-molecule antagonist from ENB Therapeutics, Inc, in registered phase 2 trials for melanoma."},{"id":"eik1005","kind":"drug","name":"EIK1005","route":"/drugs/eik1005/","status":"phase-2","tldr":"EIK1005 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for colorectal cancer, endometrial cancer."},{"id":"gecacitinib","kind":"drug","name":"Gecacitinib","route":"/drugs/gecacitinib/","status":"phase-2","tldr":"Gecacitinib is an oral kinase inhibitor from Suzhou Zelgen Biopharmaceuticals Co.,Ltd, in registered phase 2 trials for cervical cancer."},{"id":"tng260","kind":"drug","name":"TNG260","route":"/drugs/tng260/","status":"phase-2","tldr":"TNG260 is a small-molecule inhibitor from Tango Therapeutics, Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer."},{"id":"onvansertib","kind":"drug","name":"Onvansertib","route":"/drugs/onvansertib/","status":"phase-2","tldr":"Onvansertib is an oral serine/threonine kinase inhibitor from Cardiff Oncology, in registered phase 2 trials for colorectal cancer."},{"id":"vistusertib","kind":"drug","name":"Vistusertib","route":"/drugs/vistusertib/","status":"phase-2","tldr":"Vistusertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer."},{"id":"ct3001","kind":"drug","name":"CT3001","route":"/drugs/ct3001/","status":"phase-2","tldr":"CT3001 is a small-molecule inhibitor from Crossignal Therapeutics, Inc., in registered phase 2 trials for colorectal cancer, pancreatic ductal adenocarcinoma."},{"id":"prtx007","kind":"drug","name":"PRTX007","route":"/drugs/prtx007/","status":"phase-2","tldr":"PRTX007 is a small-molecule inhibitor from Primmune Therapeutics, Inc., in registered phase 2 trials for melanoma."},{"id":"merestinib","kind":"drug","name":"Merestinib","route":"/drugs/merestinib/","status":"phase-2","tldr":"Merestinib is an oral kinase inhibitor from Eli Lilly and Company, in registered phase 2 trials for metastatic cancer."},{"id":"lvgn6051","kind":"drug","name":"LVGN6051","route":"/drugs/lvgn6051/","status":"phase-2","tldr":"LVGN6051 is a monoclonal antibody from Lyvgen Biopharma Holdings Limited, in registered phase 2 trials for head and neck squamous cell carcinoma."},{"id":"amo959","kind":"drug","name":"AMO959","route":"/drugs/amo959/","status":"phase-2","tldr":"AMO959 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for prostate cancer."},{"id":"sotevtamab","kind":"drug","name":"Sotevtamab","route":"/drugs/sotevtamab/","status":"phase-2","tldr":"Sotevtamab is a monoclonal antibody from Alethia Biotherapeutics, in registered phase 2 trials for colorectal cancer."},{"id":"tilt-123","kind":"drug","name":"TILT-123","route":"/drugs/tilt-123/","status":"phase-2","tldr":"TILT-123 is an oncolytic virus from TILT Biotherapeutics Ltd., in registered phase 2 trials for ovarian cancer."},{"id":"au-007","kind":"drug","name":"AU-007","route":"/drugs/au-007/","status":"phase-2","tldr":"AU-007 is a monoclonal antibody from Aulos Bioscience, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer."},{"id":"or502","kind":"drug","name":"OR502","route":"/drugs/or502/","status":"phase-2","tldr":"OR502 is a monoclonal antibody from OncoResponse, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer."},{"id":"pamiparib","kind":"drug","name":"Pamiparib","route":"/drugs/pamiparib/","status":"phase-3","tldr":"Pamiparib is an oral parp inhibitor from BeiGene, in registered phase 3 trials for ovarian cancer."},{"id":"radotinib","kind":"drug","name":"Radotinib","route":"/drugs/radotinib/","status":"phase-3","tldr":"Radotinib is an oral kinase inhibitor from Il-Yang Pharm. Co., Ltd., in registered phase 3 trials for chronic myeloid leukaemia."},{"id":"ponsegromab","kind":"drug","name":"Ponsegromab","route":"/drugs/ponsegromab/","status":"phase-3","tldr":"Ponsegromab is a monoclonal antibody from Pfizer, in registered phase 3 trials for pancreatic ductal adenocarcinoma."},{"id":"wjb001","kind":"drug","name":"WJB001","route":"/drugs/wjb001/","status":"phase-2","tldr":"WJB001 is a small-molecule inhibitor from Wigen Biomedicine Technology (Shanghai) Co., Ltd., in registered phase 2 trials for metastatic cancer."},{"id":"mhb039a","kind":"drug","name":"MHB039A","route":"/drugs/mhb039a/","status":"phase-2","tldr":"MHB039A is a bispecific antibody from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer."},{"id":"mhb036c","kind":"drug","name":"MHB036C","route":"/drugs/mhb036c/","status":"phase-2","tldr":"MHB036C is an antibody-drug conjugate from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer."},{"id":"flonoltinib","kind":"drug","name":"Flonoltinib","route":"/drugs/flonoltinib/","status":"phase-2","tldr":"Flonoltinib is an oral kinase inhibitor from Chengdu Zenitar Biomedical Technology Co., Ltd, in registered phase 2 trials for myeloproliferative neoplasms."},{"id":"samuraciclib","kind":"drug","name":"Samuraciclib","route":"/drugs/samuraciclib/","status":"phase-2","tldr":"Samuraciclib is an oral cdk inhibitor from Pfizer, in registered phase 2 trials for metastatic cancer, HR-positive / HER2-negative breast cancer."},{"id":"jmt203","kind":"drug","name":"JMT203","route":"/drugs/jmt203/","status":"phase-2","tldr":"JMT203 is a monoclonal antibody from Shanghai JMT-Bio Inc., in registered phase 2 trials for non-small-cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer."},{"id":"emavusertib","kind":"drug","name":"Emavusertib","route":"/drugs/emavusertib/","status":"phase-2","tldr":"Emavusertib is an oral serine/threonine kinase inhibitor from Curis, Inc., in registered phase 2 trials for chronic lymphocytic leukaemia, brain and spinal cord tumours."},{"id":"doc1021","kind":"drug","name":"DOC1021","route":"/drugs/doc1021/","status":"phase-2","tldr":"DOC1021 is a cancer vaccine from Diakonos Oncology Corporation, in registered phase 2 trials for glioma & glioblastoma, melanoma."},{"id":"jbi-802","kind":"drug","name":"JBI-802","route":"/drugs/jbi-802/","status":"phase-2","tldr":"JBI-802 is a small-molecule inhibitor from Jubilant Therapeutics Inc., in registered phase 2 trials for myeloproliferative neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms."},{"id":"befotertinib","kind":"drug","name":"Befotertinib","route":"/drugs/befotertinib/","status":"phase-2","tldr":"Befotertinib is an oral kinase inhibitor from Betta Pharmaceuticals Co., Ltd., in registered phase 2 trials for non-small-cell lung cancer."},{"id":"camonsertib","kind":"drug","name":"Camonsertib","route":"/drugs/camonsertib/","status":"phase-2","tldr":"Camonsertib is an oral serine/threonine kinase inhibitor from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer."},{"id":"selicrelumab","kind":"drug","name":"Selicrelumab","route":"/drugs/selicrelumab/","status":"phase-2","tldr":"Selicrelumab is a monoclonal antibody from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer."},{"id":"fluzoparib","kind":"drug","name":"Fluzoparib","route":"/drugs/fluzoparib/","status":"phase-2","tldr":"Fluzoparib is an oral parp inhibitor from Risen (Suzhou) Pharma Tech Co., Ltd., in registered phase 2 trials for metastatic cancer."},{"id":"evexomostat","kind":"drug","name":"Evexomostat","route":"/drugs/evexomostat/","status":"phase-2","tldr":"Evexomostat is a small-molecule inhibitor from SynDevRx, Inc., in registered phase 2 trials for metastatic cancer."},{"id":"tst003","kind":"drug","name":"TST003","route":"/drugs/tst003/","status":"phase-2","tldr":"TST003 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for colorectal cancer."},{"id":"obi-902","kind":"drug","name":"OBI-902","route":"/drugs/obi-902/","status":"phase-2","tldr":"OBI-902 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer."},{"id":"cyh33","kind":"drug","name":"CYH33","route":"/drugs/cyh33/","status":"phase-2","tldr":"CYH33 is a small-molecule inhibitor from Haihe Biopharma Co., Ltd., in registered phase 2 trials for ovarian cancer."},{"id":"farletuzumab-ecteribulin","kind":"drug","name":"Farletuzumab ecteribulin","route":"/drugs/farletuzumab-ecteribulin/","status":"phase-2","tldr":"Farletuzumab ecteribulin is an antibody-drug conjugate from Eisai Inc., in registered phase 2 trials for metastatic cancer."},{"id":"imp1734","kind":"drug","name":"IMP1734","route":"/drugs/imp1734/","status":"phase-2","tldr":"IMP1734 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for metastatic cancer."},{"id":"rv001v","kind":"drug","name":"RV001V","route":"/drugs/rv001v/","status":"phase-2","tldr":"RV001V is a cancer vaccine from RhoVac APS, in registered phase 2 trials for prostate cancer."},{"id":"dr-01","kind":"drug","name":"DR-01","route":"/drugs/dr-01/","status":"phase-2","tldr":"DR-01 is a monoclonal antibody from Dren Bio, in registered phase 2 trials for peripheral T-cell lymphomas."},{"id":"lp-184","kind":"drug","name":"LP-184","route":"/drugs/lp-184/","status":"phase-2","tldr":"LP-184 is a small-molecule inhibitor from Lantern Pharma Inc., in registered phase 2 trials for triple-negative breast cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma."},{"id":"skb105","kind":"drug","name":"SKB105","route":"/drugs/skb105/","status":"phase-2","tldr":"SKB105 is an antibody-drug conjugate from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., in registered phase 2 trials for metastatic cancer."},{"id":"rvu120","kind":"drug","name":"RVU120","route":"/drugs/rvu120/","status":"phase-2","tldr":"RVU120 is a small-molecule inhibitor from Ryvu Therapeutics SA, in registered phase 2 trials for acute myeloid leukaemia."},{"id":"tuspetinib","kind":"drug","name":"Tuspetinib","route":"/drugs/tuspetinib/","status":"phase-2","tldr":"Tuspetinib is an oral kinase inhibitor from Aptose Biosciences Inc., in registered phase 2 trials for myelodysplastic syndromes / neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms."},{"id":"avzo-023","kind":"drug","name":"AVZO-023","route":"/drugs/avzo-023/","status":"phase-2","tldr":"AVZO-023 is a small-molecule inhibitor from Avenzo Therapeutics, Inc., in registered phase 2 trials for metastatic cancer."},{"id":"vudalimab","kind":"drug","name":"Vudalimab","route":"/drugs/vudalimab/","status":"phase-2","tldr":"Vudalimab is a bispecific antibody from Xencor, Inc., in registered phase 2 trials for ovarian cancer, endometrial cancer, cervical cancer."},{"id":"np137","kind":"drug","name":"NP137","route":"/drugs/np137/","status":"phase-2","tldr":"NP137 is a monoclonal antibody from NETRIS Pharma, in registered phase 2 trials for endometrial cancer, cervical cancer."},{"id":"tqb3702","kind":"drug","name":"TQB3702","route":"/drugs/tqb3702/","status":"phase-2","tldr":"TQB3702 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for non-Hodgkin lymphoma."},{"id":"rem-422","kind":"drug","name":"REM-422","route":"/drugs/rem-422/","status":"phase-2","tldr":"REM-422 is a small-molecule inhibitor from Remix Therapeutics, in registered phase 2 trials for salivary gland cancers."},{"id":"upifitamab-rilsodotin","kind":"drug","name":"Upifitamab rilsodotin","route":"/drugs/upifitamab-rilsodotin/","status":"phase-2","tldr":"Upifitamab rilsodotin is an antibody-drug conjugate from Mersana Therapeutics, in registered phase 2 trials for ovarian cancer, non-small-cell lung cancer."},{"id":"stp938","kind":"drug","name":"STP938","route":"/drugs/stp938/","status":"phase-2","tldr":"STP938 is a small-molecule inhibitor from Step Pharma, SAS, in registered phase 2 trials for non-Hodgkin lymphoma."},{"id":"tqb3909","kind":"drug","name":"TQB3909","route":"/drugs/tqb3909/","status":"phase-2","tldr":"TQB3909 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for metastatic cancer."},{"id":"obi-992","kind":"drug","name":"OBI-992","route":"/drugs/obi-992/","status":"phase-2","tldr":"OBI-992 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer."},{"id":"theo-260","kind":"drug","name":"THEO-260","route":"/drugs/theo-260/","status":"phase-2","tldr":"THEO-260 is an oncolytic virus from Theolytics Limited, in registered phase 2 trials for ovarian cancer."},{"id":"pbp1510","kind":"drug","name":"PBP1510","route":"/drugs/pbp1510/","status":"phase-2","tldr":"PBP1510 is a monoclonal antibody from Prestige Biopharma Limited, in registered phase 2 trials for pancreatic ductal adenocarcinoma."},{"id":"rnk05047","kind":"drug","name":"RNK05047","route":"/drugs/rnk05047/","status":"phase-2","tldr":"RNK05047 is a targeted protein degrader from Ranok Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer."},{"id":"bexmarilimab","kind":"drug","name":"Bexmarilimab","route":"/drugs/bexmarilimab/","status":"phase-2","tldr":"Bexmarilimab is a monoclonal antibody from Faron Pharmaceuticals Ltd, in registered phase 2 trials for acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, myelodysplastic syndromes / neoplasms."},{"id":"inlexisertib","kind":"drug","name":"Inlexisertib","route":"/drugs/inlexisertib/","status":"phase-2","tldr":"Inlexisertib is an oral serine/threonine kinase inhibitor from Deciphera Pharmaceuticals, LLC, in registered phase 2 trials for metastatic cancer."},{"id":"tenalisib","kind":"drug","name":"Tenalisib","route":"/drugs/tenalisib/","status":"phase-2","tldr":"Tenalisib is an oral pi3k inhibitor from Rhizen Pharmaceuticals SA, in registered phase 2 trials for triple-negative breast cancer."},{"id":"mitazalimab","kind":"drug","name":"Mitazalimab","route":"/drugs/mitazalimab/","status":"phase-2","tldr":"Mitazalimab is an antibody-drug conjugate from Alligator Bioscience AB, in registered phase 2 trials for pancreatic ductal adenocarcinoma."},{"id":"ipg1094","kind":"drug","name":"IPG1094","route":"/drugs/ipg1094/","status":"phase-2","tldr":"IPG1094 is a small-molecule inhibitor from Nanjing Immunophage Biotech Co., Ltd, in registered phase 2 trials for metastatic cancer."},{"id":"vibostolimab","kind":"drug","name":"Vibostolimab","route":"/drugs/vibostolimab/","status":"phase-2","tldr":"Vibostolimab is a monoclonal antibody from Merck Sharp & Dohme LLC, in registered phase 2 trials for non-small-cell lung cancer."},{"id":"boserolimab","kind":"drug","name":"Boserolimab","route":"/drugs/boserolimab/","status":"phase-2","tldr":"Boserolimab is a monoclonal antibody from Merck Sharp & Dohme LLC, in registered phase 2 trials for non-small-cell lung cancer."},{"id":"hst-1011","kind":"drug","name":"HST-1011","route":"/drugs/hst-1011/","status":"phase-2","tldr":"HST-1011 is a small-molecule inhibitor from HotSpot Therapeutics, Inc, in registered phase 2 trials for metastatic cancer."},{"id":"spartalizumab","kind":"drug","name":"Spartalizumab","route":"/drugs/spartalizumab/","status":"phase-2","tldr":"Spartalizumab is a monoclonal antibody from Novartis Pharmaceuticals, in registered phase 2 trials for myelodysplastic syndromes / neoplasms."},{"id":"sabatolimab","kind":"drug","name":"Sabatolimab","route":"/drugs/sabatolimab/","status":"phase-2","tldr":"Sabatolimab is a monoclonal antibody from Novartis Pharmaceuticals, in registered phase 2 trials for myelodysplastic syndromes / neoplasms."},{"id":"evm14","kind":"drug","name":"EVM14","route":"/drugs/evm14/","status":"phase-2","tldr":"EVM14 is a cancer vaccine from Everest Medicines (Beijing) Co., Ltd., in registered phase 2 trials for metastatic cancer."},{"id":"pimicotinib","kind":"drug","name":"Pimicotinib","route":"/drugs/pimicotinib/","status":"phase-2","tldr":"Pimicotinib is an oral kinase inhibitor from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, in registered phase 2 trials for tenosynovial giant cell tumour."},{"id":"vb15010","kind":"drug","name":"VB15010","route":"/drugs/vb15010/","status":"phase-2","tldr":"VB15010 is a small-molecule inhibitor from Zhejiang Yangli Pharmaceutical Technology Co., Ltd., in registered phase 2 trials for ovarian cancer, prostate cancer, pancreatic ductal adenocarcinoma."},{"id":"tqb2868","kind":"drug","name":"TQB2868","route":"/drugs/tqb2868/","status":"phase-2","tldr":"TQB2868 is a bispecific antibody from Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., in registered phase 2 trials for pancreatic ductal adenocarcinoma."},{"id":"ard103","kind":"drug","name":"ARD103","route":"/drugs/ard103/","status":"phase-2","tldr":"ARD103 is a car-t cell therapy from ARCE Therapeutics, Inc., in registered phase 2 trials for acute myeloid leukaemia, myelodysplastic syndromes / neoplasms."},{"id":"vactosertib","kind":"drug","name":"Vactosertib","route":"/drugs/vactosertib/","status":"phase-2","tldr":"Vactosertib is an oral serine/threonine kinase inhibitor from MedPacto, Inc., in registered phase 2 trials for osteosarcoma."},{"id":"adavosertib","kind":"drug","name":"Adavosertib","route":"/drugs/adavosertib/","status":"phase-2","tldr":"Adavosertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for triple-negative breast cancer."},{"id":"nuv-1511","kind":"drug","name":"NUV-1511","route":"/drugs/nuv-1511/","status":"phase-2","tldr":"NUV-1511 is a small-molecule inhibitor from Nuvation Bio Inc., in registered phase 2 trials for prostate cancer, pancreatic ductal adenocarcinoma, ovarian cancer."}]}